MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-18-2026
Charles River Laboratories International Operating Cycle 2011-2026 | CRL
Annual Operating Cycle Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65 | 67.7 | 67.7 | 64 | 65 | 70.6 | 107 | 109 | 121 | 113 | 113 | 112 | 112 | 110 | 105 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 121 | 64 | 93.4 |
Quarterly Operating Cycle Charles River Laboratories International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68.2 | 67.4 | 68.5 | - | 116 | - | - | - | 111 | 106 | 68.3 | - | 35.5 | 32.7 | 66.9 | - | 66.4 | 62.6 | 68 | 71.3 | 75.8 | 82.6 | 73 | 67.9 | 70.2 | 71.3 | 74.4 | 71.6 | 73.6 | 73.6 | 83.3 | 82 | 84.5 | 83.6 | 81.3 | 71.2 | 78 | 76.5 | 81.5 | 69.6 | 70.5 | 72.6 | 75.2 | 71.4 | 71.9 | 69 | 72.9 | 69.6 | 68.9 | 68.7 | 66.4 | - | 66.5 | 65.1 | 61.9 | - | 60.8 | 58.5 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 116 | 32.7 | 72.5 |
Operating Cycle of other stocks in the Diagnostics research industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
170 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
489 | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
161 | $ 118.25 | -1.27 % | $ 35.9 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
275 | $ 22.5 | 9.44 % | $ 242 M |  China |
 |
Aspira Women's Health
AWH
|
1.2 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
134 | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
164 | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
114 | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 22.42 | 27.6 % | $ 1.19 B | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
91.7 | - | - | $ 19.8 B | USA |
 |
Enzo Biochem
ENZ
|
206 | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
1.79 K | $ 1.46 | 2.82 % | $ 1.94 M | USA |
 |
Castle Biosciences
CSTL
|
97.9 | $ 24.56 | -0.24 % | $ 682 M | USA |
 |
Global Cord Blood Corporation
CO
|
202 | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
11.8 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
185 | - | 0.12 % | $ 80.1 M | China |
 |
Medpace Holdings
MEDP
|
50.4 | $ 515.65 | -0.56 % | $ 14.9 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.22 K | - | - | $ 10.7 B | USA |
 |
Danaher Corporation
DHR
|
143 | $ 193.78 | -2.18 % | $ 138 B | USA |
 |
Interpace Biosciences
IDXG
|
96 | $ 2.2 | - | $ 9.73 M | USA |
 |
Heska Corporation
HSKA
|
177 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
216 | - | -20.0 % | $ 1.06 M | USA |
 |
NeoGenomics
NEO
|
102 | $ 8.16 | -5.99 % | $ 1.05 B | USA |
 |
Neogen Corporation
NEOG
|
213 | $ 9.24 | -1.91 % | $ 2 B | USA |
 |
Illumina
ILMN
|
198 | $ 132.72 | 0.35 % | $ 21.1 B | USA |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 16.13 | -0.25 % | $ 488 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
89 | $ 28.63 | -1.58 % | $ 20 B |  Niderland |
 |
Guardant Health
GH
|
128 | $ 85.7 | 0.99 % | $ 10.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
172 | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
275 | $ 2.83 | -3.41 % | $ 91.8 K | USA |
 |
Biomerica
BMRA
|
204 | $ 2.2 | 4.27 % | $ 5.05 M | USA |
 |
Senseonics Holdings
SENS
|
104 | $ 6.77 | -1.88 % | $ 282 M | USA |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 115.58 | -0.79 % | $ 9.53 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
71.8 | $ 266.36 | -0.14 % | $ 22.2 B | USA |
 |
Soleno Therapeutics
SLNO
|
1.04 K | $ 52.57 | - | $ 2.67 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K |  Israel |
 |
Neuronetics
STIM
|
69.1 | $ 1.4 | 0.72 % | $ 92.3 M | USA |
 |
Myriad Genetics
MYGN
|
95.1 | $ 5.0 | -3.66 % | $ 463 M | USA |
 |
Lantheus Holdings
LNTH
|
121 | $ 83.92 | -0.02 % | $ 5.66 B | USA |
 |
Thermo Fisher Scientific
TMO
|
70 | $ 516.0 | -2.95 % | $ 195 B | USA |
 |
Trinity Biotech plc
TRIB
|
299 | $ 0.7 | -0.54 % | $ 61.9 M | Irlanda |
 |
Quest Diagnostics Incorporated
DGX
|
54.2 | $ 191.46 | 0.02 % | $ 21.3 B | USA |
 |
ENDRA Life Sciences
NDRA
|
412 | $ 5.17 | 0.58 % | $ 4.07 M | USA |
 |
Twist Bioscience Corporation
TWST
|
96.1 | $ 56.23 | -2.41 % | $ 3.36 B | USA |